Who are CHF 4226 pMDI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Indacaterol and tiotropium, CHF 1535, LABA/LAMA or Placebo inhalation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chf-4226-pmdi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

CHF 4226 pMDI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CHF 4226 pMDI (CHF 4226 pMDI) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: LABA/LAMA combination bronchodilator. Area: Respiratory.

phase 2 LABA/LAMA combination bronchodilator Beta-2 adrenergic receptor and M3 muscarinic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

CHF 4226 pMDI (CHF 4226 pMDI) — Chiesi Farmaceutici S.p.A.. CHF 4226 is an inhaled dual bronchodilator combining a long-acting beta-2 agonist and long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CHF 4226 pMDI TARGET	CHF 4226 pMDI	Chiesi Farmaceutici S.p.A.	phase 2	LABA/LAMA combination bronchodilator	Beta-2 adrenergic receptor and M3 muscarinic receptor
Indacaterol and tiotropium	Indacaterol and tiotropium	University of Dundee	marketed	LABA/LAMA combination bronchodilator	Beta-2 adrenergic receptor and M3 muscarinic receptor
CHF 1535	CHF 1535	Chiesi Farmaceutici S.p.A.	phase 3	LABA/LAMA combination (Long-Acting Beta-2 Agonist / Long-Acting Muscarinic Antagonist)	Beta-2 adrenergic receptor and M3 muscarinic receptor
LABA/LAMA or Placebo inhalation	LABA/LAMA or Placebo inhalation	Shanghai Pulmonary Hospital, Shanghai, China	marketed	LABA/LAMA combination bronchodilator	Beta-2 adrenergic receptor and muscarinic M3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (LABA/LAMA combination bronchodilator class)

Chiesi Farmaceutici S.p.A. · 1 drug in this class
Shanghai Pulmonary Hospital, Shanghai, China · 1 drug in this class
University of Dundee · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CHF 4226 pMDI — Competitive Intelligence Brief. https://druglandscape.com/ci/chf-4226-pmdi. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing